Liver transplantation for cholestatic diseases

Czech version

Authors: M. Hlavatý; L. Bajer; S. Fraňková; P. Drastich
Authors‘ workplace: Klinika hepatogastroenterologie, Institut klinické a experimentální medicíny, Praha
Published in: Gastroent Hepatol 2024; 78(2): 115-122
Category: Hepatology
doi: https://doi.org/10.48095/ccgh2024115

Overview

Cholestatic liver diseases are characterized by their progressive nature and limited conservative treatment options. Liver transplantation is the only effective method of treatment for the terminal stage. Before the era of liver transplantation, patients with cholestatic disease had a significantly reduced life expectancy. Liver transplantation is now indicated not only for patients with chronic liver failure or hepatobiliary malignancy, but also for those with reduced quality of life from cholestatic symptoms. Post-transplant care is particularly specific because of the presence of immune-associated diseases, such as inflammatory bowel disease in patients with primary sclerosing cholangitis. Recurrence of the underlying disease in the liver graft is a common long-term complication that can negatively affect graft survival and overall life expectancy. Despite the risk of recurrence, the long-term outcomes of liver transplantation for cholestatic disease are excellent, achieving longer survival compared to other transplant recipients.

Keywords:

liver transplantation – primary sclerosing cholangitis – primary biliary cholangitis – secondary sclerosing cholangitis – liver sarcoidosis

Sources

1. Visseren T, Erler NS, Polak WG et al. Recurrence of primary sclerosing cholangitis after liver transplantation – analysing the European Liver Transplant Registry and beyond. Transpl Int 2021; 34 (8): 1455–1467. doi: 10.1111/tri. 13925.

2. Pena Polanco NA, Levy C, Martin EF. Cholestatic liver diseases after liver transplant. Clin Liver Dis 2017; 21 (2): 403–420. doi: 10.1016/ j.cld.2016.12.011.

3. Karlsen TH, Folseraas T, Thorburn D et al. Primary sclerosing cholangitis – a comprehensive review. J Hepatol 2017; 67 (6): 1298–1323. doi: 10.1016/j.jhep.2017.07.022.

4. van Munster KN, Mol B, Goet JC et al. Disease burden in primary sclerosing cholangitis in the Netherlands: a long-term follow-up study. Liver Int 2023; 43 (3): 639–648. doi: 10.1111/liv. 15471.

5. Bowlus CL, Arrivé L, Bergquist A et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023; 77 (2): 659–702. doi: 10.1002/hep. 32771.

6. Chazouilleres O, Beuers U, Bergquist A et al. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022; 77 (3): 761–806. doi: 10.1016/j.jhep.2022.05.011.

7. Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2012; 36 (5): 420–436. doi: 10.1016/j.clinre.2011.10.007.

8. Sapisochin G, Javle M, Lerut J et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020; 104 (6): 1125–1130. doi: 10.1097/TP. 0000000000003212.

9. Goldberg DS, Camp A, Martinez-Camacho A et al. Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl 2013; 19 (3): 250–258. doi: 10.1002/lt.23587.

10. Trilianos P, Agnihotri A, Ucbilek E et al. Greater biosynthetic liver dysfunction in primary sclerosing cholangitis suggests co-existent or impending cholangiocarcinoma. J Clin Transl Hepatol 2016; 4 (1): 1–4. doi: 10.14218/JCTH.2015. 00048.

11. Song J, Li Y, Bowlus CL et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC): a comprehensive review. Clin Rev Allergy Immunol 2020; 58 (1): 134–149. doi: 10.1007/s12016-019-08764-7.

12. Boberg KM, Bergquist A, Mitchell S et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37 (10): 1205–1211. doi: 10.1080/003655202760373434.

13. Heimbach JK, Gores GJ, Haddock MG et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24 (2): 201–207. doi: 10.1055/s-2004-828 896.

14. Sapisochin G, Ivanics T, Heimbach J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? Hepatology 2022; 75 (2): 455–472. doi: 10.1002/hep.32 258.

15. Carbone M, Della Penna A, Mazzarelli C et al. Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD) – a European Society of Organ Transplantation (ESOT) Consensus Statement. Transpl Int 2023; 36: 11729. doi: 10.3389/ti.2023.11729.

16. Gordon FD, Goldberg DS, Goodrich NP et al. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: comparison of risk factors between living and deceased donor recipients. Liver Transpl 2016; 22 (9): 1214–1222. doi: 10.1002/lt.24496.

17. Loftus EV, Harewood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54 (1): 91–96. doi: 10.1136/gut. 2004.046615.

18. Joshi D, Bjarnason I, Belgaumkar A et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013; 33 (1): 53–61. doi: 10.1111/j.1478-3231.2011.02 677.x.

19. Spadaccini M, Aghemo A, Caprioli F et al. Safety of vedolizumab in liver transplant recipients: a systematic review. United European Gastroenterol J 2019; 7 (7): 875–880. doi: 10.1177/2050640619858050.

20. Westerouen van Meeteren MJ, Hayee B, Inderson A et al. Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis. J Crohns Colitis 2017; 11 (9): 1146–1151. doi: 10.1093/ecco-jcc/jjx 057.

21. Schregel I, Ramos GP, Ioannou S et al. Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study. Clin Gastroenterol Hepatol 2023; 21 (13): 3448.e3–3450.e3. doi: 10.1016/ j.cgh.2023.01.014.

22. Singh S, Loftus EV, Talwalkar JA. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Am J Gastroenterol 2013; 108 (9): 1417–1425. doi: 10.1038/ajg.2013.163.

23. Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 2020; 17 (2): 93–110. doi: 10.1038/s41 575-019-0226-7.

24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67 (1): 145–172. doi: 10.1016/j.jhep.2017.03. 022.

25. Lindor KD, Bowlus CL, Boyer J et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69 (1): 394–419. doi: 10.1002/hep.30145.

26. Goet JC, Murillo Perez CF, Harms MH et al. A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis. Am J Gastroenterol 2021; 116 (7): 1514–1522. doi: 10.14309/ajg.0000000000001285.

27. Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57 (3): 675–688. doi: 10.1016/j.jhep.2012.04.015.

28. Brooling J, Leal R. Secondary sclerosing cholangitis: a review of recent literature. Curr Gastroenterol Rep 2017; 19 (9): 44. doi: 10.1007/s11894-017-0583-8.

29. Ruemmele P, Hofstaedter F, Gelbmann CM. Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 2009; 6 (5): 287–295. doi: 10.1038/nrgastro.2009.46.

30. Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol 2015; 48 (2): 198–206. doi: 10.1007/s12016-014-8430-2.

ORCID autorů

M. Hlavatý 0009-0007-1718-436X,

L. Bajer 0000-0002-3815-3120,

S. Fraňková 0000-0002-1462-5920,

P. Drastich 0000-0002-5656-9242.

Doručeno/Submitted: 26. 3. 2024

Přijato/Accepted: 2. 4. 2024

MUDr. Mojmír Hlavatý

Klinika hepatogastroenterologie

Institut klinické a experimentální medicíny

Vídeňská 1958/9

140 21 Praha 4